Smith Nicholas Conrad 4

What Happened
Nicholas Conrad Smith, Chief Financial Officer of Alto Neuroscience (ANRO), was granted a derivative award for 200,000 shares on February 11, 2026 (transaction code A). The reported price/exercise was $0.00, and the award is subject to a multi-year vesting schedule — it is a compensation grant (not an open-market purchase or sale) and does not represent immediately tradable shares.

Key Details

• Transaction date: 2026-02-11; Form 4 filed: 2026-02-13 (timely filing).
• Transaction type/code: Grant/Award (A) — derivative securities reported.
• Amount: 200,000 shares underlying the award; reported price/exercise: $0.00.
• Vesting (Footnote F1): 25% (50,000 shares) vests on Feb 11, 2027; then 1/48 of the total shares (~4,166.7 shares) vests monthly thereafter to cover the remaining 150,000 shares.
• Shares owned after transaction: not disclosed in the information provided.
• No indication this was a sale or purchase of marketable stock — it’s a compensation grant tied to continued service.

Context
Derivative awards like options or restricted stock units are common executive compensation and are typically used to retain executives through vesting schedules; they are not an immediate bullish or bearish market signal by themselves. Because these shares vest over time, the award motivates continued employment rather than immediate trading.